A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Eli Lilly and Company
Janssen Research & Development, LLC
Janssen Research & Development, LLC
AstraZeneca
Amgen
iOnctura
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Pfizer
RemeGen Co., Ltd.
Shanghai Chest Hospital
M.D. Anderson Cancer Center
AstraZeneca
University of Rochester
H. Lee Moffitt Cancer Center and Research Institute
Abramson Cancer Center at Penn Medicine
Cullinan Therapeutics Inc.
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Tesaro, Inc.
Memorial Sloan Kettering Cancer Center
University Health Network, Toronto
Merck Sharp & Dohme LLC
Peking University Cancer Hospital & Institute
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
Thomas Jefferson University
Inspirna, Inc.
UNC Lineberger Comprehensive Cancer Center
Boehringer Ingelheim
Blueprint Medicines Corporation
Innovent Biologics (Suzhou) Co. Ltd.
AstraZeneca
Arcus Biosciences, Inc.
The Netherlands Cancer Institute
Jiangsu Hansoh Pharmaceutical Co., Ltd.
University of Chicago
Canadian Cancer Trials Group
Sichuan University
Cantargia AB
Blueprint Medicines Corporation
Memorial Sloan Kettering Cancer Center
Aileron Therapeutics, Inc.
Innovent Biologics (Suzhou) Co. Ltd.
Merck Sharp & Dohme LLC
Novartis
Tianjin Medical University Cancer Institute and Hospital